Urinary biomarkers in lupus nephritis
- PMID: 20127204
- PMCID: PMC2917506
- DOI: 10.1007/s12016-010-8197-z
Urinary biomarkers in lupus nephritis
Abstract
Renal involvement in patients with systemic lupus erythematosus in the form of severe lupus nephritis is associated with a significant burden of morbidity and mortality. Conventional laboratory biomarkers in current use have not been very successful in anticipating disease flares, predicting renal histology, or decreasing unwanted outcomes. Since early treatment is associated with improved clinical results, it is thus essential to identify new biomarkers with substantial predictive power to reduce the serious sequelae of this difficult to control lupus manifestation. Indeed, considerable efforts and progress have been made over the last few years in the search for novel biomarkers. Since urinary biomarkers are more easily obtainable with much less risk to the patient than repeat renal biopsies, and these may more accurately discern between renal disease and other organ manifestations than their serum counterparts, there has been tremendous interest in studying new candidate urine biomarkers. Below, we review several promising urinary biomarkers under investigation, including total proteinuria and microalbuminuria, urinary proteomic signatures, and the individual inflammatory mediators interleukin-6, vascular cell adhesion molecule-1, CXCL16, IP-10, and tumor necrosis factor-like weak inducer of apoptosis.
Figures


Similar articles
-
Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis.J Immunol. 2007 Nov 15;179(10):7166-75. doi: 10.4049/jimmunol.179.10.7166. J Immunol. 2007. PMID: 17982109 Clinical Trial.
-
Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.Arthritis Res Ther. 2018 Jan 11;20(1):6. doi: 10.1186/s13075-017-1498-3. Arthritis Res Ther. 2018. PMID: 29325582 Free PMC article.
-
Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis.J Clin Immunol. 2011 Oct;31(5):848-56. doi: 10.1007/s10875-011-9555-1. Epub 2011 Jun 21. J Clin Immunol. 2011. PMID: 21691937
-
Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1.Lupus. 2019 Mar;28(3):265-272. doi: 10.1177/0961203319826695. Epub 2019 Feb 2. Lupus. 2019. PMID: 30712490 Review.
-
Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review.Am J Nephrol. 2021;52(7):559-571. doi: 10.1159/000517852. Epub 2021 Aug 13. Am J Nephrol. 2021. PMID: 34515043
Cited by
-
Urinary biomarkers in lupus nephritis.J Transl Autoimmun. 2020 Feb 13;3:100042. doi: 10.1016/j.jtauto.2020.100042. eCollection 2020. J Transl Autoimmun. 2020. PMID: 32743523 Free PMC article. Review.
-
Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study.Autoimmune Dis. 2015;2015:962046. doi: 10.1155/2015/962046. Epub 2015 Jul 12. Autoimmune Dis. 2015. PMID: 26246906 Free PMC article.
-
Paradoxical role of Breg-inducing cytokines in autoimmune diseases.J Transl Autoimmun. 2019 Aug 17;2:100011. doi: 10.1016/j.jtauto.2019.100011. eCollection 2019 Dec. J Transl Autoimmun. 2019. PMID: 32743499 Free PMC article. Review.
-
Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus.Lupus Sci Med. 2022 May;9(1):e000631. doi: 10.1136/lupus-2021-000631. Lupus Sci Med. 2022. PMID: 35568436 Free PMC article.
-
Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis.Int J Mol Sci. 2019 May 27;20(10):2606. doi: 10.3390/ijms20102606. Int J Mol Sci. 2019. PMID: 31137925 Free PMC article.
References
-
- Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–424. - PubMed
-
- Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982–1995. Arch Intern Med. 2000;160:3136–3140. - PubMed
-
- Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046–2051. - PubMed
-
- Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563–1569. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources